Tarsus Pharmaceuticals's total assets for Q1 2025 were $500.75M, an increase of 32.83% from the previous quarter. TARS total liabilities were $158.29M for the fiscal quarter, a 3.83% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.